|
Fixed-duration (FD) ibrutinib (I) + venetoclax (V) for first-line (1L) treatment (tx) of chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Three-year follow-up from the FD cohort of the phase 2 CAPTIVATE study. |
| |
|
Consulting or Advisory Role - Sanofi |
Research Funding - Abbvie; Acerta Pharma; Cyclacel; Genentech; Gilead Sciences; GlaxoSmithKline/Novartis; Janssen; Juno Therapeutics; Kite, a Gilead company; Loxo; miRagen; Oncternal Therapeutics, Inc; Pharmacyclics; Sunesis Pharmaceuticals; Xencor |
| |
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Bayer; BeiGene; Bristol-Myers Squibb/Celgene; Genentech; Infinity Pharmaceuticals; Janssen; MEI Pharma; Merck; MorphoSys; Novartis; Pharmacyclics; Seagen; TG Therapeutics |
Research Funding - AstraZeneca (Inst); Pharmacyclics (Inst) |
| |
|
Consulting or Advisory Role - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Celgene; Juno Therapeutics; Pharmacyclics |
Speakers' Bureau - AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Pharmacyclics/Janssen |
Research Funding - Acerta Pharma (Inst); BeiGene (Inst); Bristol-Myers Squibb/Sanofi (Inst); Celgene (Inst); Juno Therapeutics (Inst); Kite, a Gilead company (Inst); Oncternal Therapeutics (Inst); Pharmacyclics (Inst); TG Therapeutics (Inst) |
| |
|
Honoraria - Abbvie; AstraZeneca; BeiGene; Pharmacyclics/Janssen |
Consulting or Advisory Role - Abbvie/Genentech; ADC Therapeutics; Ascentage Pharma; AstraZeneca; BeiGene; Epizyme; Janssen Oncology; Pharmacyclics; TG Therapeutics |
Research Funding - Celgene; Genentech; Janssen; TG Therapeutics |
| |
|
Employment - Moores Cancer Center |
Stock and Other Ownership Interests - Oncternal Therapeutics, Inc |
Honoraria - Abbvie; AstraZeneca; Dava Oncology; Genentech; Gilead Sciences; Janssen; Pharmacyclics |
Consulting or Advisory Role - Abbvie; Dava Oncology; Genentech; Janssen; Pharmacyclics |
Speakers' Bureau - Abbvie/Genentech; DAVA Pharmaceuticals; Gilead Sciences; Pharmacyclics/Janssen; Verastem/Pharmacyclics |
Research Funding - Breast Cancer Research Foundation (Inst); California Institute for Regenerative Medicine (CIRM) (Inst); Leukemia and Lymphoma Society (Inst); National Cancer Institute (Inst); NIH (Inst); Oncternal Therapeutics, Inc (Inst); Pharmacyclics/Janssen (Inst) |
Patents, Royalties, Other Intellectual Property - Cirmtuzumab was developed by Thomas J. Kipps in the Thomas J. Kipps laboratory and licensed by the University of California to Oncternal Therapeutics, Inc., which provided stock options and research funding to the Thomas J. Kipps laboratory. (Inst) |
Travel, Accommodations, Expenses - Abbvie/Pharmacyclics; AstraZeneca; Breast Cancer Research Foundation; Celgene; Dava Oncology; Genentech/Roche; Gilead Sciences; Janssen; TG Therapeutics; Verastem |
| |
|
Honoraria - Abbvie; Janssen; Takeda |
Consulting or Advisory Role - Abbvie; Janssen; Takeda |
Speakers' Bureau - Janssen |
Research Funding - Janssen |
| |
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Pharmacyclics; Verastem |
Speakers' Bureau - Abbvie; AstraZeneca; BeiGene; Janssen; Pharmacyclics |
Research Funding - MEI Pharma; Pharmacyclics; TeneoBio; TG Therapeutics |
| |
|
|
Consulting or Advisory Role - Abbvie |
Speakers' Bureau - Abbvie |
Travel, Accommodations, Expenses - Roche |
| |
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Beigene; Janssen |
Speakers' Bureau - Abbvie; AstraZeneca; Beigene; Janssen |
| |
|
Honoraria - Abbvie; AstraZeneca; CSL Behring; Gilead Sciences; Janssen; Merck; Mundipharma; Roche; Takeda |
Consulting or Advisory Role - Abbvie; AstraZeneca; Celgene; CSL Behring; Gilead Sciences; Janssen; Merck; Mundipharma; Novartis; Takeda |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); BeiGene (Inst); Celgene (Inst); Epizyme (Inst); Gilead Sciences (Inst); Janssen (Inst); Merck (Inst); Pharmacyclics (Inst); Roche (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Roche |
| |
|
Employment - Sanofi Pasteur (I) |
Stock and Other Ownership Interests - Sanofi Pasteur (I) |
Research Funding - Abbvie (Inst); Abbvie/Pharmacyclics (Inst); Genentech (Inst); Merck (Inst); Regeneron (Inst); Roche (Inst) |
| |
|
Stock and Other Ownership Interests - Commonwealth Serum Laboratories (CSL) |
Honoraria - Abbvie; AstraZeneca; Janssen Oncology; Merck; Mundipharma; Roche; Sandoz; Takeda |
Consulting or Advisory Role - Abbvie; AstraZeneca; Janssen Oncology; Kyowa Kirin International |
Speakers' Bureau - AstraZeneca; Janssen-Ortho |
| |
|
No Relationships to Disclose |
| |
|
Employment - Abbvie; Becton Dickinson |
Stock and Other Ownership Interests - Abbvie; Becton Dickinson |
Other Relationship - DiscernDx; InterVenn Biosciences |
| |
|
|
Stock and Other Ownership Interests - Abbvie |
| |
|
Employment - Abbvie/Pharmacyclics |
Stock and Other Ownership Interests - Abbvie/Pharmacyclics |
| |
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
| |
|
Employment - Pharmacyclics |
Stock and Other Ownership Interests - Abbvie |
| |
|
Honoraria - Abbvie; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; ArQule; BeiGene; Dynamo Therapeutics; Gilead Sciences; Janssen Oncology; Juno Therapeutics; Juno/Celgene/Bristol-Myers Squibb; Lilly; MEI Pharma; MSD; Roche; Sunesis Pharmaceuticals |
Consulting or Advisory Role - Abbvie; Acerta Pharma/AstraZeneca; Adaptive Biotechnologies; ArQule; BeiGene; Dynamo Therapeutics; Gilead Sciences; Janssen; Juno Therapeutics; Lilly; MEI Pharma; MSD; Roche; Sunesis Pharmaceuticals |
Research Funding - Abbvie; AstraZeneca; Gilead Sciences; Janssen Oncology; Novartis; Sunesis Pharmaceuticals |
| |
|
Honoraria - Abbvie; Beigene; Janssen-Cilag; Loxo/Lilly; Novartis; Pharmacyclics; Roche/Genentech |
Consulting or Advisory Role - Abbvie; BeiGene; Janssen; Loxo; Roche |
Research Funding - Abbvie (Inst); BeiGene (Inst); Janssen-Cilag (Inst) |